CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms

[1]  Jacques Fellay,et al.  A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1 , 2007, Science.

[2]  Amalio Telenti,et al.  Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1 , 2007, Nature Genetics.

[3]  Ronald S Veazey,et al.  Paucity of CD4 (cid:1) CCR5 (cid:1) T cells is a typical feature of natural SIV hosts , 2022 .

[4]  J. Casanova,et al.  Human genetics of infectious diseases: Fundamental insights from clinical studies. , 2006, Seminars in immunology.

[5]  David R Bangsberg,et al.  Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. , 2006, JAMA.

[6]  M. Lederman,et al.  Biology of CCR5 and its role in HIV infection and treatment. , 2006, JAMA.

[7]  J. Goedert,et al.  KIR/HLA Pleiotropism: Protection against Both HIV and Opportunistic Infections , 2006, PLoS pathogens.

[8]  S. Staprans,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on March 1, 2013. For personal use , 2006 .

[9]  Mario Roederer,et al.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.

[10]  Grégoire Altan-Bonnet,et al.  Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell–dendritic cell interaction , 2006, Nature.

[11]  D. Douek,et al.  HIV disease: fallout from a mucosal catastrophe? , 2006, Nature Immunology.

[12]  H. Schuitemaker,et al.  Low-Level CD4+ T Cell Activation Is Associated with Low Susceptibility to HIV-1 Infection1 , 2005, The Journal of Immunology.

[13]  M. McElrath,et al.  Combined Effect of CCR5-Δ32 Heterozygosity and the CCR5 Promoter Polymorphism −2459 A/G on CCR5 Expression and Resistance to Human Immunodeficiency Virus Type 1 Transmission , 2005, Journal of Virology.

[14]  H. Schmidtmayerova,et al.  Macrophage Inflammatory Protein 1α Inhibits Postentry Steps of Human Immunodeficiency Virus Type 1 Infection via Suppression of Intracellular Cyclic AMP , 2005, Journal of Virology.

[15]  Antonio Lanzavecchia,et al.  T cell costimulation by chemokine receptors , 2005, Nature Immunology.

[16]  Qingsheng Li,et al.  Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells , 2005, Nature.

[17]  T. Beaty,et al.  The Effect of RANTES Chemokine Genetic Variants on Early HIV-1 Plasma RNA Among African American Injection Drug Users , 2005, Journal of acquired immune deficiency syndromes.

[18]  B. Rovin,et al.  The Influence of CCL 3 L 1 Gene – Containing Segmental Duplications on HIV-1 / AIDS Susceptibility , 2009 .

[19]  I. Hickie,et al.  Does genotype mask the relationship between psychological factors and immune function? , 2005, Brain, Behavior, and Immunity.

[20]  R. Kaslow,et al.  Influence of host genetic variation on susceptibility to HIV type 1 infection. , 2005, The Journal of infectious diseases.

[21]  F. Miedema,et al.  Pre-seroconversion immune status predicts the rate of CD4 T cell decline following HIV infection , 2004, AIDS.

[22]  John P. Moore,et al.  The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. , 2004, AIDS research and human retroviruses.

[23]  B. Connolly,et al.  The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P. , 2004, Virology.

[24]  Todd M. Allen,et al.  Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection , 2003, AIDS (London).

[25]  R. Koup,et al.  T cell dynamics in HIV-1 infection. , 2003, Annual review of immunology.

[26]  Sebastian Bonhoeffer,et al.  Glancing behind virus load variation in HIV-1 infection. , 2003, Trends in microbiology.

[27]  M. Lederman,et al.  CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. , 2003, Clinical immunology.

[28]  M. Hudgens,et al.  What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. , 2003, The Journal of infectious diseases.

[29]  N. Maeda,et al.  CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. , 2003, Atherosclerosis.

[30]  D. Taub,et al.  MIP-1α and MIP-1β differentially mediate mucosal and systemic adaptive immunity , 2003 .

[31]  R. Duggirala,et al.  Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. , 2001, The Journal of infectious diseases.

[32]  Bernhard Moser,et al.  Lymphocyte traffic control by chemokines , 2001, Nature Immunology.

[33]  J. Cyster,et al.  Chemokines as regulators of T cell differentiation , 2001, Nature Immunology.

[34]  T. Curiel,et al.  Macrophage-Derived Dendritic Cells Have Strong Th1-Polarizing Potential Mediated by β-Chemokines Rather Than IL-121 , 2000, The Journal of Immunology.

[35]  P. Henkart,et al.  β‐chemokines inhibit activation‐induced death of lymphocytes from HIV‐infected individuals , 2000 .

[36]  A. J. Valente,et al.  Evolution of Human and Non-human Primate CC Chemokine Receptor 5 Gene and mRNA , 2000, The Journal of Biological Chemistry.

[37]  S. Hammer,et al.  Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. , 2000, AIDS research and human retroviruses.

[38]  F. Marincola,et al.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M J Dolan,et al.  Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Mao,et al.  LD78β, A Non-allelic Variant of Human MIP-1α (LD78α), Has Enhanced Receptor Interactions and Potent HIV Suppressive Activity* , 1999, The Journal of Biological Chemistry.

[41]  J. Goedert,et al.  Genetic acceleration of AIDS progression by a promoter variant of CCR5. , 1998, Science.

[42]  F. Miedema,et al.  In vivo delayed-type hypersensitivity skin test anergy in human immunodeficiency virus type 1 infection is associated with T cell nonresponsiveness in vitro. , 1998, The Journal of infectious diseases.

[43]  P. O’Connell,et al.  Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression , 1998, Nature Medicine.

[44]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[45]  W. Karpus,et al.  Differential CC chemokine-induced enhancement of T helper cell cytokine production. , 1997, Journal of immunology.

[46]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[47]  D. Taub,et al.  β Chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production , 1996, Journal of leukocyte biology.

[48]  M. Clerici,et al.  In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. , 1995, The Journal of infectious diseases.

[49]  S. Zolla-Pazner,et al.  Delayed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression. Department of Veterans Affairs Cooperative Study Group. , 1994, The Journal of infectious diseases.

[50]  Laurie J. Smith,et al.  The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. Military Medical Consortium for Applied Retroviral Research. , 1993, Journal of acquired immune deficiency syndromes.

[51]  C. Hendrix,et al.  Delayed-Type Hypersensitivity Skin Testing Predicts Progression to AIDS in HIV-infected Patients , 1993, Annals of Internal Medicine.

[52]  B. Lesourd,et al.  Multitest CMI for standardized measurement of delayed cutaneous hypersensitivity and cell-mediated immunity. Normal values and proposed scoring system for healthy adults in the U.S.A. , 1984, Annals of allergy.

[53]  D. Taub,et al.  MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. , 2003, Blood.

[54]  B. Walker,et al.  Immunologic control of HIV-1. , 2002, Annual review of medicine.

[55]  S. Zolla-Pazner,et al.  Delayed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression. Department of Veterans Affairs Cooperative Study Group. , 1994, The Journal of infectious diseases.